- Home
- Products
- Customized ADCs
- FAT1
- Anti-FAT1-SMCC-MDC ADC
Anti-FAT1-SMCC-MDC ADC (CAT#: ADC-W-128)
This ADC product is comprised of an anti-fat R2 monoclonal antibody (clone Bat0206) conjugated via a SMCC linker to MDC. The MDC is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MDC binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- Product Information
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Antibody clone #
- Bat0206
- Name
- FAT1
- Alternative Names
- FAT; ME5; CDHF7; CDHR8; hFat1
- Target Entrez Gene ID
- 2195
- Target UniProt ID
- Q14517
- Overview
- This gene is an ortholog of the Drosophila fat gene, which encodes a tumor suppressor essential for controlling cell proliferation during Drosophila development. The gene product is a member of the cadherin superfamily, a group of integral membrane proteins characterized by the presence of cadherin-type repeats. In addition to containing 34 tandem cadherin-type repeats, the gene product has five epidermal growth factor (EGF)-like repeats and one laminin A-G domain. This gene is expressed at high levels in a number of fetal epithelia. Its product probably functions as an adhesion molecule and/or signaling receptor, and is likely to be important in developmental processes and cell communication. Transcript variants derived from alternative splicing and/or alternative promoter usage exist, but they have not been fully described.
- Overview
- Anti-FAT1 antibody, clone # Bat0206
- Clone #
- Bat0206
- Species Reactivity
- Human
- Name
- SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate)
- Description
- Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
- Name
- MDC (maytansinol)
- Description
- Derived from Maytansinoid,a group of cytotoxins structurally similar to rifamycin, geldanamycin, and ansatrienin. The eponymous natural cytotoxic agent maytansine is a 19-member lactam (ansa
macrolide) structure originally isolated from the Ethiopian shrub Maytenus ovatus. Maytansinoids can bind to tubulin at or near the vinblastine-binding site, which interfere the formation of microtubules and depolymerize already formed microtubules, inducing mitotic arrest in the intoxicated cells.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-RTN4 (Ozanezumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1745)
- Anti-C-kit-SMCC-DM1 ADC-4 (CAT#: ADC-W-072)
- Anti-CTAA16.88 (Votumumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-2046)
- Anti-ITGA2B (Abciximab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1465)
- Anti-CD40 (Dacetuzumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-899)
- Anti-TNFRSF17-VC-MMAE ADC-13 (CAT#: ADC-W-274)
- Anti-TPBG-Mc-MMAD ADC-4 (CAT#: ADC-W-160)
- Anti-MS4A1 (Ibritumomab)-MC-MMAF ADC (CAT#: ADC-W-1552)
- Anti-MYL (Imciromab)-MC-MMAF ADC (CAT#: ADC-W-2170)
- Anti-IGF1R (Dalotuzumab)-SPDB-DM4 ADC (CAT#: ADC-W-1263)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-128. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-582 | Anti-ERBB2-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-496 | Anti-EGFR-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-2604 | Anti-ITGB3 (Tadocizumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-2620 | Anti-NCAM1 (Lorvotuzumab )-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-2598 | Anti-GPNMB (Glembatumumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-129 | Anti-MS4A1-SMCC-MDC ADC-2 | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | MDC (maytansinol) |
| ADC-W-126 | Anti-EGFR-S-3AA-MDC ADC-2 | S-3AA | MDC (maytansinol) |
| ADC-W-127 | Anti-EGFR-SMCC-MDC ADC-2 | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | MDC (maytansinol) |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.